Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Operating Costs and Expenses:
General and administrative	$ 1,644	$ 2,147	$ 3,734	$ 4,573
Research and development	4,831	7,164	10,891	15,319
Total Operating Costs and Expenses	6,475	9,311	14,625	19,892
Loss from Operations	(6,475)	(9,311)	(14,625)	(19,892)
Other Income:
Change in fair value of warrant liability	2,159	3,513	7,249	3,015
Interest income	1	34	3	35
Total Other Income	2,160	3,547	7,252	3,050
Net Loss	(4,315)	(5,764)	(7,373)	(16,842)
Net Loss Attributable to Non-controlling Interest	(60)	(82)	(272)	(315)
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries	$ (4,255)	$ (5,682)	$ (7,101)	$ (16,527)
Net Loss Per Share - Basic and Dilutive	$ (0.03)	$ (0.06)	$ (0.06)	$ (0.18)
Net Loss Per Share - Dilutive	$ (0.03)	$ (0.10)	$ (0.06)	$ (0.21)
Weighted average number of shares outstanding during the period - Basic	123,005,220	91,015,733	120,241,593	90,921,243
Weighted average number of shares outstanding during the period - Dilutive	123,005,220	93,930,540	120,241,593	92,651,215